LY4167586 in Obesity or Overweight With or Without Type 2 Diabetes

Phase 1, randomised, double-blind trial of LY4167586 in obesity, Overweight and type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at 89 weeks. Planned start Oct 2026; status: not yet recruiting.